Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
GLP-1 receptor agonists are proving their worth beyond diabetes and obesity clinics. A real-world Spanish cohort study found that rheumatology patients on GLP-1 RAs lost meaningful weight, improved blood sugar and lipid levels, and showed reduced inflammatory markers — especially those with chronic inflammatory arthritis. The findings add to a growing body of evidence supporting GLP-1 use across rheumatologic care settings.
GLP-1 receptor agonists (RAs) are already reshaping obesity and diabetes care — and now real-world data suggest they may have a meaningful role in rheumatology too. A retrospective Spanish cohort study of 119 rheumatology outpatients on GLP-1 RA therapy found sustained weight loss and improvements in blood glucose and lipid levels over 12 months. Crucially, inflammatory markers also declined — particularly in patients with chronic inflammatory arthritis — hinting at a potential anti-inflammatory effect beyond metabolic benefits.
A separate large US registry study of over 60,000 rheumatology patients confirmed rising GLP-1 use (from 0.1% in 2018 to 6.8% in 2024) and meaningful weight loss at one year, with tirzepatide outperforming semaglutide. Both studies noted that Black individuals and those with higher social deprivation had reduced odds of weight loss response, flagging important equity concerns.
By the Numbers:
Why it matters: These findings support expanding GLP-1 RA use in rheumatology practice, where obesity and metabolic comorbidities are common. The possible anti-inflammatory signal adds an exciting new dimension — though larger, prospective studies are needed to confirm it.
